Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm

Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis. Despite the availability of advanced technology in diagnostic tools that can boost the procedure, the...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamad Yusof, Umi Kalsom, Mashohor, Syamsiah, Hanafi, Marsyita, Md Noor, Sabariah, Zainal, Norsafina
Format: Article
Published: Elsevier BV 2023
Online Access:http://psasir.upm.edu.my/id/eprint/108186/
https://linkinghub.elsevier.com/retrieve/pii/S235234092300584X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis. Despite the availability of advanced technology in diagnostic tools that can boost the procedure, the morphological assessment of bone marrow trephine (BMT) images remains critical to confirm and differentiate MPN subtypes. This paper reports a histopathological imagery dataset that was created to focus on the most common MPN from the Philadelphia Chromosome (Ph)-negative type, namely Essential Thrombocythemia (ET), Polycythemia Vera (PV), and Primary Myelofibrosis (MF). The dataset consisted of 300 BMT images that can be used to enable computer vision applications, such as image segmentation, disease classification, and object recognition, in assisting the classification of the MPN disease. Ethical approval was obtained from the Ministry of Health, Malaysia and the bone marrow trephine images were captured using a digital microscope from the Olympus model (BX41 Dual head microscope) with x10, x20, and x40 lens types. The development of comprehensive tools deployed from this dataset can assist medical practitioners in diagnosing diseases, thus overcoming the current challenges.